InflaRx (NASDAQ: IFRX)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-04 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.340 | -0.360 | -0.0200 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of InflaRx (NASDAQ: IFRX) through any online brokerage.
There are no as such competitors for InflaRx.
The latest price target for InflaRx (NASDAQ: IFRX) was reported by Credit Suisse on Friday, May 13, 2022. The analyst firm set a price target for 2.00 expecting IFRX to rise to within 12 months (a possible 156.08% upside). 9 analyst firms have reported ratings in the last year.
The stock price for InflaRx (NASDAQ: IFRX) is $0.781 last updated June 24, 2022, 8:00 PM UTC.
There are no upcoming dividends for InflaRx.
InflaRx’s Q2 earnings are confirmed for Thursday, August 4, 2022.
There is no upcoming split for InflaRx.
InflaRx is in the Healthcare sector and Biotechnology industry. They are listed on the NASDAQ.